Intro
Brand Name: Abilify, Abilify Maintena, Aristada, Aristada Initio
Class: 2nd Generation/Atypical Antipsychotic
MOA: Partial dopamine agonist
Indications
FDA Indications: Schizophrenia, Acute mania/mixed mania, Bipolar maintenance, Adjunct for MDD, Irritability associated with autistic disorder 6-17y/o, Tourette’s disorder ages 6-18y/o, Acute agitation associated with schizophrenia or bipolar disorder
Off-label uses: Adjust to SSRIs for OCD
Dosing
Forms:
Tablet: 2, 5, 10, 15, 20, 30
Orally disintegrating tablet: 10, 15
Oral solution: 1mg/mL
Abilify Maintena: 300, 400
Abilify Asimtufii: 720, 960
Aristada: 441, 662, 882, 1064
Initio: 675
Starting:
Schizophrenia:
->Initial: 10-15mg qDay
->Max: 30mg qDay
Adjunct for depression:
->Initial: 2-5mg qDay
->Max: 15mg qDay
Autism:
->Initial: 2mg qDay
->Max: 15mg qDay
Tourette’s disorder:
->Depends on weight
Agitation associated with schizophrenia or bipolar disorder:
->Initial: 9.75mg/1.3mL once injected IM
->Max: 30mg/day (9.75mg up to 3 doses) injected IM
Gems
-Oral solution and tablet doses are interchangable on 1:1mg basis up to 25mg, with one exception: patients receiving 30mg tablet should receive 25mg of oral solution (due to oral solution’s higher bioavailability)